American Journal of Cardiology
Volume 106, Issue 6 , Pages 787-792 , 15 September 2010

Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Controlled by Pravastatin 40 mg monotherapy

  • Michel Farnier, MD, PhD

      Affiliations

    • Point Medical, Dijon, France
    • Corresponding Author InformationCorresponding author: Tel: 33-3-80-70-38-13; fax: 33-3-80-70-38-14
    • ,
  • Jean Ducobu, MD

      Affiliations

    • University of Mons, Mons, Belgium
    • ,
  • Leszek Bryniarski, MD, PhD

      Affiliations

    • Institute of Cardiology and Jagiellonian University Medical College, Kraków, Poland

Received 3 March 2010 ,Revised 6 May 2010 ,Accepted 6 May 2010.

  • Image Result

    Participant flow chart and statistical analysis sets. F160 = fenofibrate 160 mg; ITT = intention-to-treat; P40 = pravastatin 40 mg.

    Participant flow chart and statistical analysis sets. F160 = fenofibrate 160 mg; ITT = intention-to-treat; P40 = pravastatin 40 mg.

  • Image Result

    Proportion of patients treated with fenofibrate 160 mg/pravastatin 40 mg (gray bars) or pravastatin 40 mg (white bars) reaching LDL cholesterol (LDL-C) and non-HDL cholesterol (non-HDL-C) goals after

    Proportion of patients treated with fenofibrate 160 mg/pravastatin 40 mg (gray bars) or pravastatin 40 mg (white bars) reaching LDL cholesterol (LDL-C) and non-HDL cholesterol (non-HDL-C) goals after 12 weeks of treatment (intention-to-treat analysis). *p <0.01; **p <0.05 versus pravastatin 40 mg.

 This study was supported by Laboratories SMB, Brussels, Belgium.

 Dr Farnier has received grant/research support and speaker’s honoraria from and served as a consultant and advisor for Astra-Zeneca (Rueil-Malmaison, France), Genzyme (St Germain-en-Laye, France), Kowa (Nagoya, Japan), Merck and Co (Whitehouse Station, New Jersey), Merck-Schering-Plough (North Wales, Pennsylvania), Novartis (Rueil-Malmaison, France), Pfizer (Paris, France), Sanofi-Aventis (Paris, France), SMB (Brussels, Belgium), Solvay (Suresnes, France) and Takeda (Paris, France). Dr Ducobu has received grant/research support and speaker’s honoraria from and served as a consultant and advisor for Astra-Zeneca (Cheshire, United Kingdom), GSK (Genval, Belgium), Lilly (Brussels, Belgium), Merck and Co, Merck-Schering-Plough, Pfizer (New York, New York), Sandoz (Cham, Switzerland), Sanofi-Aventis, SMB and Solvay (Ixelles, Belgium). Dr Bryniarski has received speaker’s honoraria from Merck and Co, Servier (Neuilly-sur-seine, France), Merck-Schering-Plough, Sanofi-Aventis and Solvay.

PII: S0002-9149(10)01041-6

doi: 10.1016/j.amjcard.2010.05.005

American Journal of Cardiology
Volume 106, Issue 6 , Pages 787-792 , 15 September 2010

Article Tools

* Image Usage & Resolution